Seagen Q4 2022 Financial & Business Update

Seagen presents fourth quarter and full year 2022 financial results and business updates, including commercial performance of key oncology products ADCETRIS, PADCEV, TUKYSA, and TIVDAK. The presentation covers financial performance, research and development progress, and 2023 outlook with anticipated product sales, regulatory milestones, and clinical trial activities.